Literature DB >> 8146133

Hospital-acquired infections: diseases with increasingly limited therapies.

M N Swartz1.   

Abstract

About 5% of patients admitted to acute-care hospitals acquire nosocomial infections. A variety of factors contribute: increasing age of patients; availability, for treatment of formerly untreatable diseases, of extensive surgical and intensive medical therapies; and frequent use of antimicrobial drugs capable of selecting a resistant microbial flora. Nosocomial infections due to resistant organisms have been a problem ever since infections due to penicillinase-producing Staphylococcus aureus were noted within a few years of the introduction of penicillin. By the 1960s aerobic Gram-negative bacilli had assumed increasing importance as nosocomial pathogens, and many strains were resistant to available antimicrobials. During the 1980s the principal organisms causing nosocomial bloodstream infections were coagulase-negative staphylococci, aerobic Gram-negative bacilli, S. aureus, Candida spp., and Enterococcus spp. Coagulase-negative staphylococci and S. aureus are often methicillin-resistant, requiring parenteral use of vancomycin. Prevalence of vancomycin resistance among enterococcal isolates from patients in intensive care units has increased, likely due to increased use of this drug. Plasmid-mediated gentamicin resistance in up to 50% of enterococcal isolates, along with enhanced penicillin resistance in some strains, leaves few therapeutic options. The emergence of Enterobacteriaceae with chromosomal or plasmid-encoded extended spectrum beta-lactamases presents a world-wide problem of resistance to third generation cephalosporins. Control of these infections rests on (i) monitoring infections with such resistant organisms in an ongoing fashion, (ii) prompt institution of barrier precautions when infected or colonized patients are identified, and (iii) appropriate use of antimicrobials through implementation of antibiotic control programs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8146133      PMCID: PMC43382          DOI: 10.1073/pnas.91.7.2420

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options.

Authors:  R C Moellering
Journal:  J Antimicrob Chemother       Date:  1991-07       Impact factor: 5.790

2.  The Combined Action of Penicillin with Streptomycin or Chloromycetin on Enterococci in Vitro.

Authors:  E Jawetz; J B Gunnison; V R Coleman
Journal:  Science       Date:  1950-03-10       Impact factor: 47.728

3.  Erythromycin-inducible resistance in Staphylococcus aureus: requirements for induction.

Authors:  B Weisblum; C Siddhikol; C J Lai; V Demohn
Journal:  J Bacteriol       Date:  1971-06       Impact factor: 3.490

4.  The nationwide nosocomial infection rate. A new need for vital statistics.

Authors:  R W Haley; D H Culver; J W White; W M Morgan; T G Emori
Journal:  Am J Epidemiol       Date:  1985-02       Impact factor: 4.897

5.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

6.  Nosocomial infections in neutropenic cancer patients.

Authors:  P S Carlisle; R Gucalp; P H Wiernik
Journal:  Infect Control Hosp Epidemiol       Date:  1993-06       Impact factor: 3.254

7.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

8.  Methicillin-resistant staphylococcal colonization and infection in a long-term care facility.

Authors:  R R Muder; C Brennen; M M Wagener; R M Vickers; J D Rihs; G A Hancock; Y C Yee; J M Miller; V L Yu
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

Review 9.  New considerations in the pathogenesis of coagulase-negative staphylococcal foreign body infections.

Authors:  G Peters
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

10.  Epidemic methicillin-resistant Staphylococcus aureus.

Authors:  B D Cookson; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

View more
  41 in total

1.  The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 2.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

3.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals.

Authors:  Carl T Bergstrom; Monique Lo; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

4.  Antimicrobial resistance: Implications for therapy of infections with common childhood pathogens.

Authors:  D P Speert
Journal:  Can J Infect Dis       Date:  1996-05

Review 5.  Genomics and antimicrobial drug discovery.

Authors:  D T Moir; K J Shaw; R S Hare; G F Vovis
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential Lipid II docking interface.

Authors:  James B Hamburger; Amanda J Hoertz; Amy Lee; Rachel J Senturia; Dewey G McCafferty; Patrick J Loll
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

7.  FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.

Authors:  B Agerberth; H Gunne; J Odeberg; P Kogner; H G Boman; G H Gudmundsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

8.  In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.

Authors:  M Cormican; G Corbett-Feeney; S Kelly; D Hughes; J Flynn; R N Jones
Journal:  Ir J Med Sci       Date:  1998 Jul-Sep       Impact factor: 1.568

Review 9.  Ecological control of the gastrointestinal tract. The role of probiotic flora.

Authors:  S Bengmark
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

10.  Evaluating treatment protocols to prevent antibiotic resistance.

Authors:  S Bonhoeffer; M Lipsitch; B R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.